Prime Medicine, Inc. (PRME)

5.14 -0.19 (-3.56%) At close: 04:00PM EDT

Prime Medicine, Inc.

21 Erie Street
Cambridge, MA 02139
United States
617 564 0013
https://primemedicine.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 234

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Keith Michael Gottesdiener M.D., Ph.D.	President, CEO, Secretary & Director	1.06M	N/A	1954
Dr. Ann L. Lee Ph.D.	Chief Technical Officer	684.78k	N/A	1962
Dr. Jeremy S. Duffield M.D., Ph.D.	Chief Scientific Officer	680.65k	N/A	1968
Dr. Andrew Anzalone M.D., Ph.D.	Co-Founder & Head of Prime Editing Platform	N/A	N/A	1987
Dr. David R. Liu Ph.D.	Co-Founder & Chair of Scientific Advisory Board	N/A	N/A	N/A
Dr. Allan Reine M.D.	Chief Financial Officer	N/A	N/A	1975
Dr. Meredith Goldwasser	Senior VP and Head of Strategy & Corporate Operations	N/A	N/A	1971
Ms. Carman Alenson CPA, M.B.A.	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	1966
Dr. Karen Brown J.D., Ph.D.	Senior Vice President of Intellectual Property & Legal Affairs	N/A	N/A	N/A
Ms. Niamh Alix	Chief Human Resources Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Corporate governance

Prime Medicine, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.